Javelin sets UK price for Dyloject

Javelin Pharmaceuticals, Inc.of Cambridge announced today announced that it has received and published its UK pricing for Dyloject, a treatment for post-operative pain.

"Today is a watershed in Javelin's evolution from a development company to a revenue-generating organization," Daniel Carr, Javelin's chief executive and chief marketing officer, said in a statement. "Pricing publication marks the UK launch of Dyloject."

Pricing was received from the Department of Health Pharmaceutical Price Regulation Scheme, the company said.
(By Chris Reidy, Globe staff)